HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.

AbstractBACKGROUND:
The dual endothelin-receptor antagonist bosentan has been reported to improve pulmonary arterial hypertension, but the role of endothelins in the pathogenesis of the condition remains uncertain. We investigated the roles of endothelin-1 (ET-1), nitric oxide (NO), vascular endothelial growth factor (VEGF), and tenascin in overcirculation-induced pulmonary hypertension in piglets, as a model of early pulmonary arterial hypertension, with or without bosentan therapy.
METHODS AND RESULTS:
Thirty 3-week-old piglets were randomized to placebo or to bosentan 15 mg/kg BID after the anastomosis of the left subclavian artery to the pulmonary arterial trunk or after a sham operation. Three months later, the animals underwent a hemodynamic evaluation followed by cardiac and pulmonary tissue sampling for morphometry, immunohistochemistry, and real-time quantitative PCR. Chronic systemic-to-pulmonary shunting increased circulating plasma ET-1, pulmonary mRNA for ET-1, ET(B) receptor, inducible NO synthase, VEGF, and pulmonary ET-1 and VEGF proteins. There were increases in myocardial mRNA for ET(A) receptor and VEGF and in myocardial VEGF protein. Pulmonary and myocardial tissue mRNA for tenascin did not change. Normalized-flow pulmonary artery pressure increased from 20 (2) to 33 (1) mm Hg [mean (SEM)], arteriolar medial thickness increased on average by 83%, and these changes were completely prevented by bosentan therapy. Right ventricular end-systolic elastance increased in proportion to pulmonary arterial elastance with or without bosentan.
CONCLUSIONS:
Experimental overcirculation-induced pulmonary arterial hypertension appears to be causally related to an activation of the pulmonary ET-1 system and as such is completely prevented by the dual endothelin receptor antagonist bosentan.
AuthorsBenoît Rondelet, François Kerbaul, Sophie Motte, Ronald van Beneden, Myriam Remmelink, Serge Brimioulle, Kathleen McEntee, Pierre Wauthy, Isabelle Salmon, Jean-Marie Ketelslegers, Robert Naeije
JournalCirculation (Circulation) Vol. 107 Issue 9 Pg. 1329-35 (Mar 11 2003) ISSN: 1524-4539 [Electronic] United States
PMID12628956 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antihypertensive Agents
  • Endothelial Growth Factors
  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Endothelins
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • RNA, Messenger
  • Sulfonamides
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Nitric Oxide
  • Bosentan
Topics
  • Animals
  • Antihypertensive Agents (therapeutic use)
  • Bosentan
  • Endothelial Growth Factors (biosynthesis, genetics)
  • Endothelin Receptor Antagonists
  • Endothelin-1 (biosynthesis, genetics)
  • Endothelins (physiology)
  • Hemodynamics
  • Hypertension, Pulmonary (etiology, metabolism, prevention & control)
  • Intercellular Signaling Peptides and Proteins (biosynthesis, genetics)
  • Lung (metabolism)
  • Lymphokines (biosynthesis, genetics)
  • Myocardium (metabolism)
  • Nitric Oxide (biosynthesis, genetics)
  • Pulmonary Artery (pathology, surgery)
  • Pulmonary Circulation
  • RNA, Messenger (biosynthesis)
  • Sulfonamides (therapeutic use)
  • Swine
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: